{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-053532","form_type":"8-K","ticker":"ENTA","cik":"0001177648","company_name":"ENANTA PHARMACEUTICALS INC","filed_at":"2024-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.553808+00:00","generated_at":"2026-06-02T21:47:12.092297+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Enanta Q2 net loss $31.2M; cash $300.3M; RSV data readouts expected in 2H 2024","bullets":["Fiscal Q2 2024 revenue $17.1M (AbbVie HCV royalty); net loss $31.2M ($1.47 loss/share) vs $37.7M loss a year ago.","Cash, equivalents, and marketable securities total $300.3M; expected runway through Q3 FY2027.","Zelicapavir Phase 2 pediatric RSV data expected 2H 2024; EDP-323 challenge study data expected Q3 2024.","KIT inhibitor development candidate for CSU targeted Q4 2024; second immunology program planned in 2024.","Expense guidance updated: R&D $125M-$145M, G&A $50M-$60M due to immunology/RSV efforts and Pfizer patent lawsuit."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-053532","json":"https://secwatch.observer/filing/0000950170-24-053532.json","markdown":"https://secwatch.observer/filing/0000950170-24-053532.md","text":"https://secwatch.observer/filing/0000950170-24-053532.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1177648/000095017024053532/0000950170-24-053532-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1177648/000095017024053532/enta-20240506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T21:47:12.092297+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b86f96e8b08bfb8837f4b8588c4728ec87c75621","claim":"ENANTA PHARMACEUTICALS INC reported fiscal quarter ended March 31, 2024 results: revenue $17.1 million, EPS a loss of $1.47 per diluted common share. Guidance reaffirmed.","evidence_excerpt":"chronic diseases with a second program this year.” Fiscal Second Quarter Ended March 31, 2024 Financial Results Total revenue for the three months ended March 31, 2024 was $17.1 million and consisted of royalty revenue from worldwide net sales of AbbVie’s hepatitis C virus (HCV) regimen MAVYRET®/MAVIRET® (glecaprevir/pibrentasvir), compared to $17.8 million for","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1177648/000095017024053532/0000950170-24-053532-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal quarter ended March 31, 2024"},{"label":"Revenue","value":"$17.1 million"},{"label":"EPS","value":"a loss of $1.47 per diluted common share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}